To introduce the therapeutic potential of targeting the transdifferentiation of ILC3s to immunosuppressive ILCs, Wang and colleagues demonstrated that depletion of this subset or IL-10 deletion suppressed tumor growth significantly and blocking TGF-β signaling through receptor deletion on ILC3s or TGF-β inhibitor treatment blocked the ILC3 to immunosuppressive ILC conversion, also controlling tumor growth. The gene discussed is TGFB1; the disease is neoplasm.